PDCD1 and metabolic dysfunction-associated steatohepatitis: In summary, the elegant work by Pfister et al.1 demonstrated pro-tumorigenic property of CD8+PD1+ T cells, and their involvement in anti-PD1 immunotherapy triggered NASH-HCC preclinical models.